In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The company’s shares opened today at p11,242.00.

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to address concerns over its business in China than on its earnings report alone.

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £140.00. The company’s shares closed ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

BRITISH pharmaceutical giant AstraZeneca said on Friday (Jan 31) that it was abandoning plans to build a £450 million (S$756.9 million) vaccine plant, a major blow to the Labour government’s plans to ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...